This is an international site for Tasigna® (Nilotinib) and is intended for Health Care Professionals outside the U.S. The information on the site is not country-specific, and may contain information that is outside the approved indications in the country in which you are located. Please contact your local Novartis representative for the latest information specific to your country.

I am a healthcare professional outside the U.S. I am a U.S. resident I am a patient outside the U.S.
Print Text Size Glossary Summary of Product Characteristics Safety Information U.S. Residents

This site is intended for Healthcare Professionals outside the U.S.

Newly Diagnosed Patients
Imatinib-resistant/intolerant
Mechanism of Action
Dosing TASIGNA

ABOUT TASIGNA

TASIGNA is evolving the treatment for patients with Philadelphia chromosome -positive (Ph+) chronic myeloid leukemia in the chronic phase (CML-CP). ENESTnd, the first-line trial of TASIGNA in newly diagnosed patients with Ph+ CML, adds to the growing body of evidence that faster and deeper reductions of Ph+ CML disease burden, such as major molecular response (MMR), can significantly improve long-term outcomes for patients.1

The information below and accompanying links will help you optimize treatment for your patients with TASIGNA, whether as a first-line or second-line treatment.1

In this section you will find:


References:
1.TASIGNA® (nilotinib) Summary of Product Characteristics. Basel, Switzerland: Novartis Pharma AG; June 2011.
2. Manley PW, Drueckes P, Fendrich G, et al. Extended kinase profile and properties of the protein kinase inhibitor nilotinib. Biochim Biophys Acta. 2010;1804(3):445-453.

TASIGNA Interactive Game

In newly diagnosed patients — More first-line power to reduce disease progression vs. imatinib.1

Dosing TASIGNA — Tips to help your patients incorporate TASIGNA into their routines.